Mutant p53 expression in fallopian tube epithelium drives cell migration

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1528-1538

  Quartuccio, Suzanne M ^a   Karthikeyan, Subbulakshmi ^a   Eddie, Sharon L ^a   Lantvit, Daniel D ^a   Hainmhire, Eoghainín Ó ^a   Modi, Dimple A ^a   Wei, Jian Jun ^b   Burdette, Joanna E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

fallopian tube; high grade serous cancer; p53 mutation

Indexed keywords

ALISERTIB; AURORA A KINASE; AURORA B KINASE; COMPLEMENTARY DNA; CYTOKERATIN 8; OVIDUCTAL GLYCOPROTEIN 1; OVIDUCTIN; POLO LIKE KINASE 4; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA BINDING; DNA SYNTHESIS; DOWN REGULATION; EPITHELIUM CELL; FALLOPIAN TUBE; FEMALE; GENE MUTATION; GENE ONTOLOGY; GENE OVEREXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MITOSIS; MOUSE; MURINE OVARIAN SURFACE EPITHELIUM; NONHUMAN; ONCOGENE K RAS; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SARCOMATOID CARCINOMA; STEM CELL; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CELL MOTION; CELL TRANSFORMATION; EPITHELIUM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NUDE MOUSE; ONCOGENE RAS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE; UTERINE TUBE;

ANIMALS; CELL GROWTH PROCESSES; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; FALLOPIAN TUBES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; MICE; MICE, NUDE; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927130471     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29528     Document Type: Article

References (50)

1. Society AC. Cancer facts and figures 2014. American Cancer Society, www.cancer.org, 2014.
2. Landen CN, Jr, Birrer MJ, Sood AK., Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26: 995-1005.
3. Medeiros F, Muto MG, Lee Y, et al., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-6.
4. Piek JM, van Diest PJ, Zweemer RP, et al., Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-6.
5. Kindelberger DW, Lee Y, Miron A, et al., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9 10.1097/01.pas.0000213335.40358.47.
6. Karst AM, Levanon K, Drapkin R., Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011; 108: 7547-52.
7. Perets R, Wyant GA, Muto KW, et al., Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013; 24: 751-65.
8. Jazaeri AA, Bryant JL, Park H, et al., Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 2011; 13: 899-911.
9. Cancer Genome Atlas Network, Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
10. Olive KP, Tuveson DA, Ruhe ZC, et al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-60.
11. Dubeau L., The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999; 72: 437-42.
12. Gross AL, Kurman RJ, Vang R, et al., Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010; 2010: 126295.
13. Morgan SE, Kim R, Wang PC, et al., Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene 2000; 19: 5010-9.
14. Terzian T, Suh YA, Iwakuma T, et al., The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-44.
15. Lee Y, Miron A, Drapkin R, et al., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
16. Cass I, Walts AE, Barbuto D, et al., A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers. Gynecol Oncol 2014; 134: 492-7.
17. Karst AM, Drapkin R., Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protocols 2012; 7: 1755-64.
18. Levanon K, Ng V, Piao HY, et al., Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010; 29: 1103-13.
19. Quartuccio SM, Lantvit DD, Bosland MC, et al., Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas. PloS One 2013; 8: e65067.
20. King SM, Quartuccio SM, Vanderhyden BC, et al., Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial-stromal interaction. Carcinogenesis 2013; 34: 1125-33.
21. Baker SJ, Markowitz S, Fearon ER, et al., Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-5.
22. Singh A, Sweeney MF, Yu M, et al., TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012; 148: 639-50.
23. Berman SD, Calo E, Landman AS, et al., Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008; 105: 11851-6.
24. Skehan P, Storeng R, Scudiero D, et al., New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
25. Hickok JR, Sahni S, Mikhed Y, et al., Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron. J Biol Chem 2011; 286: 41413-24.
26. Miyoshi I, Takahashi K, Kon Y, et al., Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation. Mol Reprod Dev 2002; 63: 168-76.
27. Sherman-Baust CA, Kuhn E, Valle BL, et al., A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol 2014; 233: 228-37.
28. Garritano S, Inga A, Gemignani F, et al., More targets, more pathways and more clues for mutant p53. Oncogenesis 2013; 2: e54.
29. Vainionpaa N, Lehto VP, Tryggvason K, et al., Alpha4 chain laminins are widely expressed in renal cell carcinomas and have a de-adhesive function. Lab Invest 2007; 87: 780-91.
30. Cheon DJ, Tong Y, Sim MS, et al., A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res 2014; 20: 711-23.
31. Zeisberg M, Neilson EG., Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-37.
32. Hwang CI, Matoso A, Corney DC, et al., Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 2011; 108: 14240-5.
33. Do TV, Xiao F, Bickel LE, et al., Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene 2014; 33: 539-49.
34. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
35. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
36. Folkins AK, Jarboe EA, Saleemuddin A, et al., A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-73.
37. Szabova L, Yin C, Bupp S, et al., Perturbation of Rb, p53 and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012; 72: 4141-53.
38. Xing D, Orsulic S., A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006; 66: 8949-53.
39. Connolly DC, Bao R, Nikitin AY, et al., Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63: 1389-97.
40. Wu R, Baker SJ, Hu TC, et al., Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 2013; 182: 1391-9.
41. Kim J, Coffey DM, Creighton CJ, et al., High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109: 3921-6.
42. Kurrey NK, K A, Bapat SA., Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155-65.
43. Kim MK, Kim MA, Kim H, et al., Expression profiles of epithelial-mesenchymal transition-associated proteins in epithelial ovarian carcinoma. BioMed Res Int 2014; 2014: 495754.
44. Wu WS, Heinrichs S, Xu D, et al., Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005; 123: 641-53.
45. Kim J, Bae S, An S, et al., Cooperative actions of p21WAF1 and p53 induce Slug protein degradation and suppress cell invasion. EMBO Rep 2014; 15: 1062-8.
46. Wang SP, Wang WL, Chang YL, et al., p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009; 11: 694-704.
47. Muller PA, Caswell PT, Doyle B, et al., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-41.
48. Solomon H, Buganim Y, Kogan-Sakin I, et al., Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci 2012; 125: 3144-52.
49. Lassus H, Staff S, Leminen A, et al., Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol 2011; 120: 11-7.
50. Wu CC, Yang TY, Yu CT, et al., p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle 2012; 11: 3433-42.